Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$5.59
$5.58
$2.50
$5.62
$577.05M0.563.34 million shs2.09 million shs
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$1.95
$1.54
$1.45
$1.95
$163.47M0.465 shsN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$5.77
+1.8%
$6.16
$5.41
$23.48
$490.88M0.41.24 million shs1.50 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$16.16
-2.5%
$17.26
$2.03
$14.36
$151.87M1.1150,104 shs436,968 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00%0.00%0.00%0.00%0.00%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%+12.39%+34.48%-32.76%-21.69%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.00%-3.08%-0.18%-14.09%-72.46%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%-9.01%-13.77%+11.29%-55.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.0955 of 5 stars
0.02.00.00.00.01.70.0
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.5356 of 5 stars
4.43.00.04.72.00.80.6
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.00
N/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00
N/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50324.61% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KURA, BDSI, NLTX, and IPHYF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
6/4/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/2/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00
4/29/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.00
4/28/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
4/8/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$36.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$166.70M3.46$0.36 per share15.42$1.90 per share2.94
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$21.77M7.51N/AN/A$0.11 per share17.73
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M9.27N/AN/A$5.32 per share1.08
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A

Latest KURA, BDSI, NLTX, and IPHYF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
N/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
0.29
2.45
2.17
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
2.60
2.60
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
64.40%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioDelivery Sciences International, Inc. stock logo
BDSI
BioDelivery Sciences International
200103.23 million92.93 millionOptionable
Innate Pharma SA stock logo
IPHYF
Innate Pharma
17983.83 million57.10 millionNot Optionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioDelivery Sciences International stock logo

BioDelivery Sciences International NASDAQ:BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Innate Pharma stock logo

Innate Pharma OTCMKTS:IPHYF

$1.95 0.00 (0.00%)
As of 06/27/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$5.77 +0.10 (+1.76%)
As of 04:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$16.16 -0.41 (-2.47%)
As of 06/27/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.